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CD1d-restricted invariant NKT cells (iNKT) exert
potent anti-tumor effects by virtue of their ability to
transactivate NK cells, dendritic cells and T lympho-
cytes. However, their use in cancer immunotherapy has
been limited by their short-lived activation followed by a
phase of long-term anergy after a single injection of the
high affinity CD1d ligand alpha-galactosylceramide
(aGC). Instead, we have demonstrated that repeated
injections of recombinant soluble aGC-loaded CD1d
molecules resulted in the sustained iNKT and NK cell
activation, which correlated with prolonged antitumor
effects when the aGC/sCD1d was fused to an anti-
tumor scFv fragment. In addition, we recently showed
that aGC/CD1d-antitumor fusion protein greatly
increased the efficacy of a therapeutic peptide/CpG-
based cancer vaccine, first as an adjuvant during T cell
priming and second, as a therapeutic agent to redirect
immune responses to the tumor site.
To optimize the synergy between iNKT cells and cyto-
toxic T lymphocytes (CTLs), we aim at conferring both
antigen specificities to the same T lymphocyte by transdu-
cing iNKT cells with high avidity MHC-I-restricted TCR,
or conversely transduce CTLs with the CD1d-restricted
iNKT invTCR. Indeed, the simultaneous triggering of trans-
duced HLA-A2/NY-ESO-I TCR and of the endogenous
iNKT TCR led to increased cytokine secretion and killing
of HLA-A2 and HER2 positive tumor cells, when pulsed
with the antigenic peptide and coated with the CD1d-anti-
HER2 fusion protein. To reduce TCR mispairing between
endogenous and transduced TCRs, we are developing
human and mouse single chain iNKT TCRs (iNKT scTv)
fused to CAR-derived activation domains. The stability
between the murine Va and Vb variable domains of the
iNKT scTv is being optimized by site-directed mutagenesis
and by spacer design. The resulting variants transduced in
MHC-I-restricted T cells are tested for their binding to
aGC/CD1d multimer and for TCR function. In vivo studies
will involve the adoptive transfer of iNKT scTv-transduced
tumor-specific CTLs in immunized mice grafted with
tumor cells co-expressing the MHC-I-restricted and CD1d-
targeted antigens.
It is expected that this approach will confer CD1d-gly-
colipid specificity to tumor-specific CD8 T cells, in
which a major advantage is the availability of a single
invariant TCR that can be offered to all patients inde-
pendently of their MHC-I haplotype.
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